Monday, 2 November 2020

PRO/AH/EDR> COVID-19 update (466): antibody trial, Kenya, WHO, global

COVID-19 -- Kenya
"Abstract
---------
'Monoclonal antibodies (mAbs) are increasingly being considered as agents to fight severe viral diseases. So far, they have essentially been selected and used on the basis of their virus-neutralizing activity and/or cell-killing activity to blunt viral propagation via direct mechanisms. There is, however, accumulating evidence that they can also induce long-lasting protective antiviral immunity by recruiting the endogenous immune system of infected individuals during the

Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?7908743&promed&0

No comments:

Post a Comment